PURPOSE: This study aimed to evaluate the safety of, immune response induced by, and efficacy of treatment with lapuleucel-T (APC8024) in patients with HER-2/neu-expressing tumors. Lapuleucel-T is an investigational active immunotherapy product consisting of autologous peripheral blood mononuclear cells, including antigen presenting cells, which are cultured ex vivo with BA7072, a recombinant fusion antigen consisting of portions of the intracellular and extracellular regions of HER-2/neu linked to granulocyte-macrophage colony-stimulating factor. EXPERIMENTAL DESIGN:Patients with metastatic breast, ovarian, or colorectal cancer whose tumors expressed HER-2 were eligible. Patients underwent leukapheresis in week 0 and received lapuleucel-T infusions in weeks 0, 2, and 4. Patients who achieved a partial response or had stable disease through week 48 were eligible for re-treatment using the same protocol and dose as their initial treatment. RESULTS:Eighteen patients were enrolled and treated. Patients showed an immune response to the immunizing antigen (BA7072) at week 8 compared with week 0 as measured by T lymphocyte proliferation and IFN-gamma enzyme-linked immunospot assay. Therapy was well tolerated. The majority (94.7%) of adverse events associated with treatment were grade 1 or 2. Two patients experienced stable disease lasting > 48 weeks. CONCLUSIONS: Autologous active cellular immunotherapy with lapuleucel-T stimulated an immune response specific to the immunizing antigen and seemed to be well tolerated. Further clinical studies to assess the clinical benefit for patients with HER/2-neu-expressing breast, ovarian, and colorectal cancer are warranted.
RCT Entities:
PURPOSE: This study aimed to evaluate the safety of, immune response induced by, and efficacy of treatment with lapuleucel-T (APC8024) in patients with HER-2/neu-expressing tumors. Lapuleucel-T is an investigational active immunotherapy product consisting of autologous peripheral blood mononuclear cells, including antigen presenting cells, which are cultured ex vivo with BA7072, a recombinant fusion antigen consisting of portions of the intracellular and extracellular regions of HER-2/neu linked to granulocyte-macrophage colony-stimulating factor. EXPERIMENTAL DESIGN:Patients with metastatic breast, ovarian, or colorectal cancer whose tumors expressed HER-2 were eligible. Patients underwent leukapheresis in week 0 and received lapuleucel-T infusions in weeks 0, 2, and 4. Patients who achieved a partial response or had stable disease through week 48 were eligible for re-treatment using the same protocol and dose as their initial treatment. RESULTS: Eighteen patients were enrolled and treated. Patients showed an immune response to the immunizing antigen (BA7072) at week 8 compared with week 0 as measured by T lymphocyte proliferation and IFN-gamma enzyme-linked immunospot assay. Therapy was well tolerated. The majority (94.7%) of adverse events associated with treatment were grade 1 or 2. Two patients experienced stable disease lasting > 48 weeks. CONCLUSIONS: Autologous active cellular immunotherapy with lapuleucel-T stimulated an immune response specific to the immunizing antigen and seemed to be well tolerated. Further clinical studies to assess the clinical benefit for patients with HER/2-neu-expressing breast, ovarian, and colorectal cancer are warranted.
Authors: Eric J Small; Paul F Schellhammer; Celestia S Higano; Charles H Redfern; John J Nemunaitis; Frank H Valone; Suleman S Verjee; Lori A Jones; Robert M Hershberg Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: B J Czerniecki; C Carter; L Rivoltini; G K Koski; H I Kim; D E Weng; J G Roros; Y M Hijazi; S Xu; S A Rosenberg; P A Cohen Journal: J Immunol Date: 1997-10-15 Impact factor: 5.422
Authors: M A Morse; Y Deng; D Coleman; S Hull; E Kitrell-Fisher; S Nair; J Schlom; M E Ryback; H K Lyerly Journal: Clin Cancer Res Date: 1999-06 Impact factor: 12.531
Authors: Elizabeth A Mittendorf; Catherine E Storrer; Craig D Shriver; Sathibalan Ponniah; George E Peoples Journal: Ann Surg Oncol Date: 2006-07-24 Impact factor: 5.344
Authors: Andrew L Coveler; Vivian Goodell; Devon J Webster; Lupe G Salazar; Patricia A Fintak; Jennifer S Childs; Doreen M Higgins; Mary L Disis Journal: Breast Cancer Res Treat Date: 2008-01-31 Impact factor: 4.872
Authors: John W Park; Michelle E Melisko; Laura J Esserman; Lori A Jones; Jami Breen Wollan; Robert Sims Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Christoph A Ritter; Marianela Perez-Torres; Cammie Rinehart; Marta Guix; Teresa Dugger; Jeffrey A Engelman; Carlos L Arteaga Journal: Clin Cancer Res Date: 2007-08-15 Impact factor: 12.531
Authors: Matthew D Galsky; Daniel D Von Hoff; Marcus Neubauer; Thomas Anderson; Mark Fleming; Yasir Nagarwala; Janine M Mahoney; Dawn Midwinter; Linda Vocila; Tal Z Zaks Journal: Invest New Drugs Date: 2010-09-22 Impact factor: 3.850